Rocket One Inc. Share Price & Technical Analysis
HOTH · $1.36
Healthcare / Biotechnology
$1.36
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to t…
Price chart
Seasonality
Jun has 3 positive and 2 negative years (last 5 years shown)
69% return in Jun, 31% avg return in past 3 year Jun month.
142% return in 2026, -45% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | 11% | -20% | -22% | 114% | 69% | – | – | – | – | – | – | 142% |
| 25 | 63% | -25% | 11% | -10% | -11% | 50% | 8% | -8% | 23% | -12% | -14% | -17% | 58% |
| 24 | 0% | -8% | 15% | -20% | 0% | -25% | -22% | 0% | 29% | 0% | -11% | -22% | -64% |
| 23 | -27% | -43% | -28% | -23% | -6% | 67% | -16% | -15% | -32% | -25% | -8% | 27% | -129% |
| 22 | -14% | 0% | 18% | -25% | -15% | -4% | 2% | 8% | -22% | -34% | -24% | 90% | -19% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Uptrend
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is based in Hoboken, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$26.01M
P/E ratio
—
52W high
$2.45
52W low
$0.49
Volume
13,53,73,715
Beta
0.58
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Rocket One Inc. share price today?
- Rocket One Inc. (HOTH) last traded around $1.36 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does HOTH have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for HOTH. Download the app for real-time alerts.
- How can I analyze Rocket One Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.